Drug Trial Radar · NCT04524871
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
518
Planned (sponsor's estimate)
Start
Nov 1, 2020
Primary completion
Jul 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Adagene Inc; Tempest Therapeutics; NiKang Therapeutics, Inc.; Immune-Onc Therapeutics
- First posted
- Aug 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Conditions
- Advanced Liver Cancers
Interventions
AtezolizumabDrug
Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Bevacizumab 15 mg/kgDrug
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
TiragolumabDrug
Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
TocilizumabDrug
Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
TPST-1120Drug
TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
Tobemstomig 2100 mgDrug
Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
Bevacizumab 10 mg/kgDrug
Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
Tobemstomig 600 mgDrug
Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Tobemstomig 1200 mgDrug
Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
ADG126Drug
ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
IO-108 1800 mgDrug
IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
NKT2152Drug
NKT2152 will be administered by mouth.
IO-108 1200 mgDrug
IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From randomization until disease progression or loss of clinical benefit (up to approximately 7-9 years)
Locations
32 sites in 7 countries. Site status is shown where the registry gives one.
UC Irvine Medical Center
Costa Mesa, California
City of Hope
Duarte, California
UC Irvine Medical Center
Orange, California
University of California San Diego Medical Center
San Diego, California
University of California San Francisco Cancer Center
San Francisco, California
UCLA Center for East
Santa Monica, California
Cherry Creek Medical Center
Aurora, Colorado
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado
UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital
Highlands Ranch, Colorado
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Kentucky - Markey Cancer Center
Lexington, Kentucky
Oregon Health & Science University
Portland, Oregon
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Parkland Health & Hospital System
Dallas, Texas
The University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
Beijing Cancer Hospital
Beijing, China
Zhongshan Hospital Fudan University
Shanghai, China
Centre Georges Francois Leclerc
Dijon, France
CHU Hôpitaux de Marseille
Marseille, France
Centre Eugène Marquis
Rennes, France
Gustave Roussy
Villejuif, France
Rambam Medical Center
Haifa, Israel
Hadassah University Medical Center
Jerusalem, Israel
Davidof Center - Rabin Medical Center
Petah Tikva, Israel
Sourasky Medical Centre
Tel Aviv, Israel
Auckland City Hospital
Auckland, New Zealand
CHA Bundang Medical Center
Gyeonggi-do, South Korea
Samsung Medical Center
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.